Syncrosome, a Preclinical CRO specialized in in vivo efficacy experiments, is pleased to welcome our new colleague, Caroline Babuleaud-Casano as our new Technical Manager. Caroline hold 2 MSc., 1 in Neurosciences and 1 in Neuro-pharmacology. During her 10 years professional experience, she has been working on various...
Vaccination is increasingly being investigated as a potential treatment for synucleinopathies, a group of neurodegenerative diseases including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies associated with α-synuclein pathology. All lack a causal therapy. Development of novel, disease-altering treatment strategies is urgently needed....
Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies, have all something in common. They all belong to a group of neurodegenerative diseases called synucleinopathies, including preclinical Parkinson, characterized by the abnormal accumulation of aggregates of α-synuclein protein in neurons, nerve fibres or glial...
Researchers from the CHU Research centre in Quebec have shown that diet can play a neuroprotective role in a preclinical Parkinson mouse model. They investigated the effects of a omega-3 polyunsaturated fatty acids-enriched diet, in the form of docosahexaenoic acid (DHA), on damaged neurons. C57BL/6...
Syncrosome, a Preclinical CRO specialized in in vivo efficacy experiments, is pleased to welcome Dr Viviana Delgado Betancourt as our new Cardiovascular Study Director. Viviana brings to the table several years of experience acquired over the courseof her thesis/PhD that focused on cardioprotection against Ischemia-Reperfusion injury...
Below a poster presented by Syncrosome during the last European Respiratory Society meeting showing interesting result concerning Pulmonary Arterial Hypertension induced on rats with Sugen with remodeling in small pulmonary arteries (PAH sugen). Results are reproducible and shows a vascular remodeling, increased Right Ventricular Systolic Pressure...
This poster has been presented at the last 2015 World Parkinson Congress in France, and shows interesting results concerning an antidyskinetic compound in a rat 6 OHDA Parkinson model. Dyskinesias are induced by LDopa, and various parameters are assessed, biochemical and symptomatic. Microdialysis is used to evaluate...
Vaccination is increasingly being investigated as a potential treatment for synucleinopathies, a group of neurodegenerative diseases including Parkinson's disease (synuclein Parkinson), multiple system atrophy, and dementia with Lewy bodies associated with α-synuclein pathology. All lack a causal therapy. Development of novel, disease-altering treatment strategies is...
Preclinical data collected in models of preclinical Parkinson disease (PD) support the neuroprotective potential of omega-3 polyunsaturated fatty acids (n-3 PUFA)-enriched diet on the dopaminergic (DAergic) system. In this study, we investigated the effects of a n-3 PUFA rich diet using a neurorescue/neurorestorative paradigm....
Alpha Synuclein Parkinson: Formation and accumulation of misfolded protein aggregates are a central hallmark of several neurodegenerative diseases. In Parkinson’s disease (PD), the aggregation-prone protein alpha-synuclein (α-syn) is the culprit. In the past few years, another piece of the puzzle has been added with data suggesting...